UNSPSC 51262410: Labetalol hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1GEV3BAW9J, chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- but more generally known as labetalol hydrochloride, which bears US NIH Compound Identifier 3869. European Medicines Agency schedules Labetalol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02844MIG.

UNSPSC 51262410 Labetalol hydrochloride is a Commodity code that nominally covers a specific antihypertensive pharmaceutical, but the recent state and local solicitation activity under this code shows a marked mismatch: the only recent opportunity posted is Seminole County, Florida's IFB for naloxone and drug deactivation systems — products unrelated to labetalol hydrochloride. The tag appears to be a data error rather than a reflection of actual procurement under this code. State and local governments do purchase pharmaceuticals and medical supplies through formal bidding, typically via county health departments, municipalities, and special-purpose health districts, but the tagging here does not support meaningful activity specifically for labetalol hydrochloride.

The Seminole County solicitation (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement required electronic bid submission, E-Verify compliance, drug-free workplace certification, and specific insurance coverage (workers' compensation, general liability, professional liability), with a two-year initial term and one-year renewal option. The contract included a three-month probationary termination clause and potential FEMA funding with attendant federal compliance requirements. This single opportunity does not establish a pattern of state and local purchasing under the labetalol code; code-level activity here appears insufficient to support a pursue decision.